Recombinant Plasmid miRNA Composition for Kinase mRNA Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Over-expression or mis-expression of kinases leads to homeostatic imbalance, resulting in diseases, and existing therapies are inadequate in addressing this issue.
Innovation Solution
Compositions comprising recombinant plasmids that encode for microRNA sequences, which are administered to upregulate the production of miRNA that target and degrade or inactivate the mRNA of specific kinases, such as Bruton's tyrosine kinase, EGF, VEGF, BRAF, ALK, HER, or FLT3, thereby reducing their bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to address kinase over-expression, then some therapeutic effect is achieved, but the therapies are inadequate and do not fully restore homeostasis
Solution Approach 1:
The patent changes the molecular parameter by introducing recombinant plasmids that encode miRNA sequences with specific complementarity to kinase mRNA. This parameter change enables precise targeting and degradation of kinase mRNA, achieving more effective homeostatic regulation compared to existing therapies.
Solution Approach 2:
The patent extracts the harmful element (kinase mRNA) from the cellular system through miRNA-mediated degradation. By specifically targeting and removing kinase mRNA, the therapy eliminates the source of homeostatic imbalance more effectively than conventional approaches.
2Productivity
If kinases are over-expressed or mis-expressed, then biological function is maintained, but homeostasis is lost and disease occurs
Solution Approach 1:
The patent implements a feedback mechanism where miRNA sequences are designed to specifically target and degrade kinase mRNA based on complementarity rules. This feedback loop restores homeostasis by reducing kinase levels when they are elevated, while maintaining normal function when kinases are appropriately expressed.
Solution Approach 2:
The therapy applies local quality by targeting specific kinase mRNA sequences with complementary miRNA. Rather than broadly suppressing all kinase activity, the patent selectively degrades only the over-expressed or mis-expressed kinase mRNA, preserving normal biological function while correcting homeostatic imbalance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively downregulate the expression of target kinases, restoring homeostasis and potentially treating associated diseases by increasing the production of miRNA that degrade or inactivate the mRNA of these kinases.
Implementation Method 1
The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule
Data Source
AI summary
The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a kinase.